<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sunthankar SD</submitter><funding>NCATS NIH HHS</funding><funding>NICHD NIH HHS</funding><funding>FDA HHS</funding><pagination>e1470-e1480</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12378003</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>53(7)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Evaluate benefits and harms of prophylactic intraoperative methylprednisolone in subpopulations undergoing infant heart surgery.&lt;h4>Design&lt;/h4>Subpopulation analyses of The Steroids to Reduce Systemic Inflammation after Infant Heart Surgery (STRESS) trial, a double-blind randomized placebo-controlled trial.&lt;h4>Setting&lt;/h4>Twenty-four congenital heart centers.&lt;h4>Patients&lt;/h4>Infants (&lt; 1 yr old) undergoing heart surgery with cardiopulmonary bypass. Patients stratified by Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Congenital Heart Surgery (STAT) mortality category, age, gestational age, and presence of chromosomal or syndromic diagnosis (CSD).&lt;h4>Interventions&lt;/h4>Methylprednisolone (30 mg/kg) vs. placebo administered into cardiopulmonar</pubmed_abstract><journal>Critical care medicine</journal><pubmed_title>Methylprednisolone for Infant Heart Surgery: Subpopulation Analyses of a Randomized Controlled Trial.</pubmed_title><pmcid>PMC12378003</pmcid><funding_grant_id>U24 TR001608</funding_grant_id><funding_grant_id>HHSN275201800003I</funding_grant_id><funding_grant_id>P50 HD106446</funding_grant_id><funding_grant_id>U18 FD006298</funding_grant_id><funding_grant_id>U01 TR001803</funding_grant_id><pubmed_authors>Sunthankar SD</pubmed_authors><pubmed_authors>Karamlou T</pubmed_authors><pubmed_authors>Van Bergen AH</pubmed_authors><pubmed_authors>Vener DF</pubmed_authors><pubmed_authors>Anderson BR</pubmed_authors><pubmed_authors>Bleiweis MS</pubmed_authors><pubmed_authors>Hill KD</pubmed_authors><pubmed_authors>Scott JP</pubmed_authors><pubmed_authors>Kannankeril PJ</pubmed_authors><pubmed_authors>Jacobs ML</pubmed_authors><pubmed_authors>Benscoter A</pubmed_authors><pubmed_authors>Baldwin HS</pubmed_authors><pubmed_authors>Alfieris G</pubmed_authors><pubmed_authors>Mettler B</pubmed_authors><pubmed_authors>Li JS</pubmed_authors><pubmed_authors>Jacobs JP</pubmed_authors><pubmed_authors>Graham EM</pubmed_authors><pubmed_authors>Eghtesady P</pubmed_authors><pubmed_authors>Blasiole B</pubmed_authors><pubmed_authors>Wald E</pubmed_authors><pubmed_authors>Husain SA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Methylprednisolone for Infant Heart Surgery: Subpopulation Analyses of a Randomized Controlled Trial.</name><description>&lt;h4>Objectives&lt;/h4>Evaluate benefits and harms of prophylactic intraoperative methylprednisolone in subpopulations undergoing infant heart surgery.&lt;h4>Design&lt;/h4>Subpopulation analyses of The Steroids to Reduce Systemic Inflammation after Infant Heart Surgery (STRESS) trial, a double-blind randomized placebo-controlled trial.&lt;h4>Setting&lt;/h4>Twenty-four congenital heart centers.&lt;h4>Patients&lt;/h4>Infants (&lt; 1 yr old) undergoing heart surgery with cardiopulmonary bypass. Patients stratified by Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Congenital Heart Surgery (STAT) mortality category, age, gestational age, and presence of chromosomal or syndromic diagnosis (CSD).&lt;h4>Interventions&lt;/h4>Methylprednisolone (30 mg/kg) vs. placebo administered into cardiopulmonar</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-05-09T17:56:05.527Z</modification><creation>2026-04-08T01:08:44.212Z</creation></dates><accession>S-EPMC12378003</accession><cross_references><pubmed>40396812</pubmed><doi>10.1097/ccm.0000000000006721</doi><doi>10.1097/CCM.0000000000006721</doi></cross_references></HashMap>